Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

Autor: Mann, Johannes F E *, Hansen, Thomas, Idorn, Thomas, Leiter, Lawrence A, Marso, Steven P, Rossing, Peter, Seufert, Jochen, Tadayon, Sayeh, Vilsbøll, Tina
Zdroj: In The Lancet Diabetes & Endocrinology November 2020 8(11):880-893
Databáze: ScienceDirect